Emanuele Cencini
Distinguished in Mantle Cell Lymphoma (MCL)

Emanuele Cencini

Siena, IT 
Distinguished in Mantle Cell Lymphoma (MCL)
Siena, IT 
OverviewLocationsClinical Research

Overview

Emanuele Cencini practices in Siena, Italy. Mr. Cencini is rated as a Distinguished expert by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), Diffuse Large B-Cell Lymphoma (DLBCL), and B-Cell Lymphoma.

His clinical research consists of co-authoring 97 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Mantle Cell Lymphoma (MCL).

Gender
Male

Locations

Siena, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug
Study Phase: Phase 3
Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Other
View 1 Less Clinical Trial

97 Total Publications

Development and implementation of the International AIDA Network Castleman's disease registry.
Development and implementation of the International AIDA Network Castleman's disease registry.
Journal: Frontiers in medicine
Published: April 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cencini's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile